PFM
VIR icon

Privium Fund Management’s Vir Biotechnology VIR Stock Holding History

Privium Fund Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24,000
Closed -$617K – 287
2022
Q1 		$617K Buy
+24,000
New +$712K 0.14% 83

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Privium Fund Management's VIR Position: Q2 2022 in Review

Privium Fund Management sold out of Vir Biotechnology (VIR) in Q2 2022, closing a stake of 24,000 shares — an estimated $617K sold.

Privium Fund Management first reported a position in VIR in Q1 2022 and held it in 1 quarter. The position peaked at $617K in Q1 2022. 212 funds tracked by Wall St. Rank hold VIR as of Q2 2022.

  • Privium Fund Management reported no remaining Vir Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Privium Fund Management sold 24,000 Vir Biotechnology shares in Q2 2022, an estimated $617K.
  • Privium Fund Management first reported a position in Vir Biotechnology in Q1 2022 and held it in 1 quarter.
  • Privium Fund Management's Vir Biotechnology position peaked at $617K in Q1 2022.
  • 212 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2022.

Based on Privium Fund Management's 13F filing for Q2 2022, filed 28 Jul 2022.